IDEXX Laboratories Inc

IDEXX Labs names Michael Erickson CEO, aiming for continuity while boosting AI‑driven veterinary diagnostics and global growth amid evolving regulation and cyber risks.

Idexx Laboratories Inc. to report 2025 Q4 and full‑year results Feb 2 2026, with a detailed analyst call covering revenue growth, margins, and 2026 guidance—key data for investors and veterinary leaders.

Idexx Laboratories: steady earnings, cutting‑edge veterinary diagnostics, robust safety and FDA/EMA‑approved products that slash turnaround times and boost pet‑care efficiency.

Explore how Idexx Laboratories’ AI‑driven veterinary diagnostics are reshaping pet health, driving revenue growth, and influencing market value.

Explore IDEXX Labs’ strategic growth: AI‑enabled diagnostics, strong subscription revenue, and global lab scale set to boost profitability and market share.

Idexx Laboratories: A deep dive into its veterinary diagnostics dominance, growth prospects in poultry and point‑of‑care markets, and the regulatory, data‑privacy, and sustainability challenges shaping its future.

Idexx Laboratories’ sharp share surge reflects strong diagnostics revenue, digital growth, and high valuation multiples—great for investors seeking tech‑health innovation but with regulatory and competition risks.

IDEXX Laboratories Q3 earnings forecast: 10‑12% sales growth, EPS up 15‑20%, analyst upgrades to “Buy” and $700 target – read why investors may profit from the next report.

Discover why IDEXX Laboratories’ recent analyst upgrades are driving a stock rally—thanks to a strong recurring revenue model, expanding market reach, and solid financials that promise long‑term growth.

IDEXX Laboratories Inc. has achieved a 97% cumulative stock appreciation over the past three fiscal years, driven by robust earnings growth, efficient cost management, and favorable market trends, positioning the company for continued success in the…